Ubs Group Ag Vir Biotechnology, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 240,113 shares of VIR stock, worth $1.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

240,113

Previous 383,188 37.34%

Holding current value

$1.65 Million

Previous $2.87 Million 38.61%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$6.74 - $10.17 $964,325 - $1.46 Million	-143,075 Reduced 37.34%	240,113 $1.76 Million
Q3 2024 Nov 14, 2024	BUY	$7.26 - $10.7 $651,316 - $959,929	89,713 Added 30.57%	383,188 $2.87 Million
Q2 2024 Aug 13, 2024	SELL	$7.63 - $12.66 $1.32 Million - $2.19 Million	-172,733 Reduced 37.05%	293,475 $2.61 Million
Q1 2024 May 13, 2024	SELL	$8.6 - $11.9 $515,759 - $713,666	-59,972 Reduced 11.4%	466,208 $4.72 Million
Q4 2023 Feb 09, 2024	BUY	$7.76 - $10.29 $1.87 Million - $2.48 Million	240,648 Added 84.28%	526,180 $5.29 Million
Q3 2023 Nov 09, 2023	BUY	$9.14 - $24.62 $682,794 - $1.84 Million	74,704 Added 35.43%	285,532 $2.68 Million
Q2 2023 Aug 11, 2023	BUY	$23.2 - $27.29 $2.06 Million - $2.42 Million	88,702 Added 72.63%	210,828 $5.17 Million
Q1 2023 May 12, 2023	SELL	$22.26 - $30.85 $3.73 Million - $5.17 Million	-167,601 Reduced 57.85%	122,126 $2.84 Million
Q4 2022 Feb 08, 2023	BUY	$19.96 - $28.22 $3.7 Million - $5.23 Million	185,199 Added 177.18%	289,727 $7.33 Million
Q3 2022 Nov 10, 2022	SELL	$18.26 - $31.1 $408,056 - $694,991	-22,347 Reduced 17.61%	104,528 $2.02 Million
Q2 2022 Aug 10, 2022	SELL	$19.08 - $26.7 $3.7 Million - $5.18 Million	-194,178 Reduced 60.48%	126,875 $3.23 Million
Q1 2022 May 16, 2022	BUY	$21.19 - $40.01 $4.78 Million - $9.02 Million	225,346 Added 235.45%	321,053 $8.26 Million
Q4 2021 Feb 14, 2022	BUY	$30.97 - $54.03 $2.33 Million - $4.07 Million	75,375 Added 370.72%	95,707 $4.01 Million
Q3 2021 Nov 15, 2021	SELL	$34.9 - $54.54 $50,919 - $79,573	-1,459 Reduced 6.7%	20,332 $884,000
Q2 2021 Aug 13, 2021	SELL	$38.75 - $51.0 $510,918 - $672,435	-13,185 Reduced 37.7%	21,791 $1.03 Million
Q1 2021 May 12, 2021	SELL	$26.34 - $83.07 $276,965 - $873,481	-10,515 Reduced 23.11%	34,976 $1.79 Million
Q4 2020 Feb 11, 2021	SELL	$25.51 - $43.38 $508,414 - $864,563	-19,930 Reduced 30.46%	45,491 $1.22 Million
Q3 2020 Nov 12, 2020	BUY	$28.28 - $53.6 $791,642 - $1.5 Million	27,993 Added 74.79%	65,421 $2.25 Million
Q2 2020 Jul 31, 2020	BUY	$27.89 - $47.86 $927,091 - $1.59 Million	33,241 Added 793.91%	37,428 $1.53 Million
Q1 2020 May 01, 2020	SELL	$12.04 - $60.2 $93,550 - $467,754	-7,770 Reduced 64.98%	4,187 $143,000
Q4 2019 Feb 14, 2020	BUY	$11.83 - $15.85 $141,451 - $189,518	11,957 New	11,957 $150,000

Others Institutions Holding VIR

# of Institutions

231

Shares Held

90M

Call Options Held

1.28M

Put Options Held

235K

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $911M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account